FIND

researchers

DISCOVER

relevant articles

PROMOTE

your research

now for free

Shrikanta Chattopadhyay

Research Profile

Chemicals & Drugs

Anatomy

Physiology

Co-author Network

Publications

TOP 3
I David Goldman; Shrikanta Chattopadhyay; Rongbao Zhao; Richard Moran
The antifolates: evolution, new agents in the clinic, and how targeting delivery via specific membrane transporters is driving the development of a next generation of folate analogs.
Shrikanta Chattopadhyay; Roni Tamari; Sang Hee Min; Rongbao Zhao; Eugenia Tsai; I David Goldman
Commentary: a case for minimizing folate supplementation in clinical regimens with pemetrexed based on the marked sensitivity of the drug to folate availability.
Shrikanta Chattopadhyay; Richard G Moran; I David Goldman
Pemetrexed: biochemical and cellular pharmacology, mechanisms, and clinical applications.

Register for free to view:

Visualized networks:

See your personal network in
sophisticated graphical views

GeoTargeted Searches:

Locate experts around the world
and connect with global collaborators

Research Profiles:

See the research activity
of experts around the globe

Geonetwork of Shrikanta Chattopadhyay (preview)

Cities where this author has publications
Cities where co-authors of this author have publications

Flash Player Required

All Publications

2010: I David Goldman; Shrikanta Chattopadhyay; Rongbao Zhao; Richard Moran
The antifolates: evolution, new agents in the clinic, and how targeting delivery via specific membrane transporters is driving the development of a next generation of folate analogs.
Current opinion in investigational drugs (London, England : 2000) 2010;11(12):1409-23.
2007: Shrikanta Chattopadhyay; Roni Tamari; Sang Hee Min; Rongbao Zhao; Eugenia Tsai; I David Goldman
Commentary: a case for minimizing folate supplementation in clinical regimens with pemetrexed based on the marked sensitivity of the drug to folate availability.
The oncologist 2007;12(7):808-15.
2007: Shrikanta Chattopadhyay; Richard G Moran; I David Goldman
Pemetrexed: biochemical and cellular pharmacology, mechanisms, and clinical applications.
Molecular cancer therapeutics 2007;6(2):404-17.
2006: Andong Qiu; Michaela Jansen; Antoinette Sakaris; Sang Hee Min; Shrikanta Chattopadhyay; Eugenia Tsai; Claudio Sandoval; Rongbao Zhao; Myles H Akabas; I David Goldman
Identification of an intestinal folate transporter and the molecular basis for hereditary folate malabsorption.
Cell 2006;127(5):917-28.
2006: Shrikanta Chattopadhyay; Rongbao Zhao; Eugenia Tsai; Vern L Schramm; I David Goldman
The effect of a novel transition state inhibitor of methylthioadenosine phosphorylase on pemetrexed activity.
Molecular cancer therapeutics 2006;5(10):2549-55.
2006: Shrikanta Chattopadhyay; Rongbao Zhao; Sergey A Krupenko; Natalia I Krupenko; I David Goldman
The inverse relationship between reduced folate carrier function and pemetrexed activity in a human colon cancer cell line.
Molecular cancer therapeutics 2006;5(2):438-49.
2005: Collins A Karikari; Michael Mullendore; James R Eshleman; Pedram Argani; Lorenzo Leoni; Shrikanta Chattopadhyay; Manuel Hidalgo; Anirban Maitra
Homozygous deletions of methylthioadenosine phosphorylase in human biliary tract cancers.
Molecular cancer therapeutics 2005;4(12):1860-6.
2005: Rongbao Zhao; Shubing Zhang; Marie Hanscom; Shrikanta Chattopadhyay; I David Goldman
Loss of reduced folate carrier function and folate depletion result in enhanced pemetrexed inhibition of purine synthesis.
Clinical cancer research : an official journal of the American Association for Cancer Research 2005;11(3):1294-301.
2004: Rongbao Zhao; Shrikanta Chattopadhyay; Marie Hanscom; I David Goldman
Antifolate resistance in a HeLa cell line associated with impaired transport independent of the reduced folate carrier.
Clinical cancer research : an official journal of the American Association for Cancer Research 2004;10(24):8735-42.
2004: Shrikanta Chattopadhyay; Yanhua Wang; Rongbao Zhao; I David Goldman
Lack of impact of the loss of constitutive folate receptor alpha expression, achieved by RNA Interference, on the activity of the new generation antifolate pemetrexed in HeLa cells.
Clinical cancer research : an official journal of the American Association for Cancer Research 2004;10(23):7986-93.
2004: Rongbao Zhao; Marie Hanscom; Shrikanta Chattopadhyay; I David Goldman
Selective preservation of pemetrexed pharmacological activity in HeLa cells lacking the reduced folate carrier: association with the presence of a secondary transport pathway.
Cancer research 2004;64(9):3313-9.
2002: Yanhua Wang; Rongbao Zhao; Shrikanta Chattopadhyay; I David Goldman
A novel folate transport activity in human mesothelioma cell lines with high affinity and specificity for the new-generation antifolate, pemetrexed.
Cancer research 2002;62(22):6434-7.